PIK3CA and cancer: One of the most successful examples of isoform-selective PI3K inhibitors would be idelalisib (CAL-101), the first-in-class PI3Kδ-selective inhibitor, which received FDA approval for cancer patients with small lymphocytic lymphoma and follicular lymphoma in 2014 [160,161].